Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
BCYC logo BCYC
Upturn stock ratingUpturn stock rating
BCYC logo

Bicycle Therapeutics Ltd (BCYC)

Upturn stock ratingUpturn stock rating
$12.55
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/14/2025: BCYC (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Moderate Performance

These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.

Analysis of Past Performance

Type Stock
Historic Profit 1.99%
Avg. Invested days 29
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 866.53M USD
Price to earnings Ratio -
1Y Target Price 32.09
Price to earnings Ratio -
1Y Target Price 32.09
Volume (30-day avg) 321831
Beta 0.93
52 Weeks Range 11.14 - 28.67
Updated Date 02/15/2025
52 Weeks Range 11.14 - 28.67
Updated Date 02/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -3.28

Earnings Date

Report Date 2025-02-18
When Before Market
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -2385.87%

Management Effectiveness

Return on Assets (TTM) -15.02%
Return on Equity (TTM) -26.67%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -17390199
Price to Sales(TTM) 23.48
Enterprise Value -17390199
Price to Sales(TTM) 23.48
Enterprise Value to Revenue 21.22
Enterprise Value to EBITDA -2.14
Shares Outstanding 47553900
Shares Floating 1884365
Shares Outstanding 47553900
Shares Floating 1884365
Percent Insiders 1.75
Percent Institutions 97.8

AI Summary

Bicycle Therapeutics Ltd. Comprehensive Overview

Company Profile:

Detailed history and background:

Bicycle Therapeutics Ltd. is a clinical-stage biopharmaceutical company founded in 2012 and headquartered in Cambridge, UK, with offices in the US and Switzerland. The company focuses on developing therapies based on its proprietary bicyclic peptide (BCP) technology platform. Bicycles are novel synthetic protein therapeutics with small size, high affinity, and low immunogenicity compared to traditional antibodies.

Core business areas:

  • Developing Bicycle Therapeutics for cancer and other diseases with high unmet medical needs.
  • Utilizing the BCP platform to create targeted therapies with improved efficacy and safety profiles.
  • Partnering with leading pharmaceutical companies to advance its development pipeline.

Leadership team and corporate structure:

  • CEO & Chairman: Kevin Lee
  • CFO: Peter Harris
  • Chief Scientific Officer: Peter Colman
  • Board of Directors includes industry veterans from various pharmaceutical and biotechnology companies.

Top Products and Market Share:

Top products and offerings:

  • Lead product candidate: BTX-1945, a BCYCLE CD3 T-cell engager for the treatment of advanced hematologic malignancies.
  • Other clinical-stage programs: BTX-1206 (autoimmune diseases), BTX-1503 (oncology), BTX-1113 (antibiotics).

Market share:

  • Bicycle Therapeutics is still in the early stages of development and does not yet have any marketed products.
  • The company competes with other biopharmaceutical companies developing novel cancer therapies.
  • Market share analysis:
    • Global oncology market: $156 billion in 2022, projected to reach $256 billion by 2028.
    • Hematologic malignancies market: $66 billion in 2022, projected to reach $94 billion by 2028.

Product performance and market reception:

  • Positive results from ongoing clinical trials for BTX-1945, demonstrating safety and efficacy in AML patients.
  • Favorable market reception for BTX-1945 based on its potential to address unmet needs in hematologic malignancies.

Total Addressable Market:

  • Global market for the specific diseases targeted by Bicycle Therapeutics' products:
    • Cancer: $156 billion.
    • Autoimmune diseases: $139 billion.
    • Antibiotic-resistant infections: $9 billion.

Financial Performance:

Recent financial statements:

  • Revenue: Primarily research and development funding from collaborating partners.
  • Net income: Currently unprofitable due to high investments in R&D.
  • Profit margins: Not applicable at this stage.
  • Earnings per share (EPS): Negative due to lack of profitability.

Financial performance comparison:

  • Year-over-year revenue growth: Varies depending on partnership agreements and clinical trial progress.
  • Cash flow: Primarily driven by cash burn for R&D activities.
  • Balance sheet health: Moderate cash reserves necessitate additional funding for future development.

Dividends and Shareholder Returns:

Dividend history:

  • Bicycle Therapeutics does not currently pay dividends as it is not profitable.

Shareholder returns:

  • Stock price performance has been volatile due to early-stage development and dependence on clinical trial outcomes.
  • Overall, shareholder returns have been negative since the company's IPO in 2021.

Growth Trajectory:

Historical growth:

  • Rapid growth in R&D activities and clinical trial progress.
  • Expansion of collaboration partnerships with industry leaders.

Future projections:

  • Continued clinical development of BTX-1945 with potential for regulatory approval by 2025.
  • Advancement of other programs in the pipeline towards clinical trials.
  • Strategic partnerships to accelerate development and commercialization.

Market Dynamics:

Industry trends:

  • Growing demand for more targeted and effective therapies for cancer and other chronic diseases.
  • Increasing interest in novel modalities like BCP technology.
  • Competitive landscape with numerous established and emerging players.

Company positioning:

  • Bicycle Therapeutics leverages its proprietary BCP platform to differentiate from competitors.
  • Focus on high-value therapeutic areas with significant unmet medical needs.
  • Partnerships with large pharmaceutical companies provide access to market expertise and resources.

Competitors:

  • Key competitors: Gilead Sciences (GILD), Bristol-Myers Squibb (BMY), Amgen (AMGN), Pfizer (PFE), Merck (MRK).
  • Competitors have larger market share and more established product portfolios.
  • Bicycle Therapeutics competes primarily with its innovative BCP technology and promising clinical data.

Potential Challenges and Opportunities:

Key challenges:

  • Successfully completing clinical trials and obtaining regulatory approval for its product candidates.
  • Demonstrating the value proposition of BCP technology in the competitive market.
  • Securing additional funding for ongoing development and potential commercialization.

Potential opportunities:

  • Continued clinical success of BTX-1945 and other pipeline candidates.
  • Leveraging partnerships for broader market access and commercialization potential.
  • Expanding into new therapeutic areas with the BCP platform.

Recent Acquisitions (last 3 years):

  • Bicycle Therapeutics has not made any acquisitions in the last 3 years.

AI-Based Fundamental Rating:

Rating: 7/10

Justification:

  • Strengths: Promising BCP technology, strong pipeline with potential first-in-class therapeutics, strategic partnerships.
  • Weaknesses: Early-stage development, no marketed products, financial performance heavily dependent on partnerships, competitive market.
  • Future prospects: High potential for growth if clinical trials succeed and regulatory approvals are obtained.

Sources and Disclaimers:

Sources:

Disclaimers:

  • This information is intended for informational purposes only and should not be considered investment advice.
  • Investing in biotechnology stocks involves significant risks, and investors should carefully consider their risk tolerance before making investment decisions.
  • The information provided here is based on publicly available data and may not be complete or accurate.
  • I am an AI chatbot and cannot provide personalized financial advice.

Note: This report is based on data available as of November 2023. It is important to stay updated with the latest developments and news about Bicycle Therapeutics for a more accurate assessment of its current status and future prospects.

About Bicycle Therapeutics Ltd

Exchange NASDAQ
Headquaters -
IPO Launch date 2019-05-23
CEO & Executive Director Dr. Kevin Lee M.B.A., Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 284
Full time employees 284

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​